Associates maternal PFAS exposure with growth trajectories in infants, suggesting health implications.
Evidence regarding maternal per- and polyfluoroalkyl substances (PFAS) exposure on offspring physical development is inconsistent. This study included 937 mother-infant pairs from the Jiashan Birth Cohort. Thirteen PFAS congeners were quantified in maternal peripheral blood at the first prenatal visit (< 16 weeks of gestation). Data on offspring weight and length from birth to 24 months of age were extracted, and Z-scores for weight-for-age (WAZ), length-for-age (LAZ), and weight-for-length (WLZ) were calculated. Group-based trajectory modeling (GBTM) was applied to fit growth trajectories. Maternal PFTrDA exposure was associated with higher likelihood of offspring in WAZ "rising" groups, specifically the "Low-start rapid-rise" (OR: 1.37, 95% CI: 1.09, 1.71), "High-start slow-rise" (OR: 1.29, 95% CI: 1.07, 1.56), and "High-start rapid-rise" (OR: 1.46, 95% CI: 1.10, 1.96) groups. PFHxS and PFNA were linked to the LAZ-"Low-start rapid-rise" group (OR: 1.48, 95% CI: 1.07, 2.05; OR: 1.24, 95% CI: 1.02, 1.51, respectively), while PFTrDA was associated with the LAZ-"High-start rapid-rise" group (OR: 1.23, 95% CI: 1.01, 1.51). Most PFAS were associated with elevated likelihood of offspring in the WLZ-"Medium-start rapid-rise" group (ORs: 1.26-1.43). Bayesian kernel machine regression further confirmed the joint effects of the PFAS mixture on rising WAZ/WLZ trajectories and PFTrDA as the key chemical driving the association with the WAZ-"High-start rapid-rise" group. These findings provide evidence for associations between maternal PFAS exposure and offspring growth trajectories during early life.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: